dr. hurvitz on fda approval of subcutaneous trastuzumab formulation in her2 breast cancer
Published 5 years ago • 1.3K plays • Length 1:00Download video MP4
Download video MP3
Similar videos
-
2:15
dr. hurvitz on neoadjuvant therapy for her2 breast cancer
-
0:43
dr. hamilton on fda approval of adjuvant pertuzumab regimen in her2 early breast cancer
-
1:58
dr. hurvitz discusses role of pertuzumab in her2 breast cancer
-
3:20
dr. hurvitz on eliminating anthracyclines in her2 breast cancer treatment
-
1:11
dr. hurvitz on importance of biosimilars in her2 breast cancer
-
1:37
dr. hurvitz on how to navigate her2-targeted therapy in breast cancer
-
2:03
dr. hurvitz on novel agents in her2-positive breast cancer
-
1:20
dr. hurvitz on the evolution of treatment in metastatic her2 breast cancer
-
1:13
dr. hurvitz on using adcs in her2 breast cancer
-
1:55
dr. hurvitz on novel emerging agents in her2 breast cancer
-
1:03
dr. hurvitz on the need for additional research with trastuzumab deruxtecan in her2 breast cancer
-
1:46
dr. hurvitz on biosimilars in breast cancer
-
2:06
phrancesca: evaluating patient satisfaction with subcutaneous pertuzumab and trastuzumab treatment
-
1:41
dr. hurvitz on toxicity associated with neratinib in her2 breast cancer
-
2:00
dr. hurvitz on neomonarch trial for hr breast cancer
-
1:22
dr. hurvitz on the findings of destiny-breast01 in her2 metastatic breast cancer
-
0:58
dr. hurvitz on treatment options for her2-positive breast cancer
-
1:29
dr. hurvitz on standards of care in her2 breast cancer
-
1:35
dr. hurvitz on therapeutics for her2 metastatic breast cancer